Neurocrine's Ingrezza study shows quality-of-life gains in TD patients
Go back to Neurocrine's Ingrezza study shows quality-of-life gains in TD patients| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 145.09 -1.14 (0.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.23 | 52 Week High | $58.46 | |||
| Open | $146.15 | 52 Week Low | $31.25 | |||
| Day High | $146.26 | P/E | N/A | |||
| Day Low | $143.45 | EPS | $-0.69 | |||
| Volume | 202,101 | |||||
